Advancing knowledge of human development, developmental disabilities, and neurodegenerative diseases.
By Emily Leclerc, Waisman Science Writer One of Carl Ross’s favorite stories is actually an account of one of his failures. In the early 2000s Ross, the former managing director of Waisman Biomanufacturing (WB), was working to make a rhinovirus (the virus that is responsible for the common cold) that could be used to test …
Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
Adeno-associated virus (AAV) is used to insert replacement genes, and its role in genetic therapy trials is expanding quickly, says Carl Ross, managing director of Waisman Biomanufacturing. The AAV production reflects the Waisman lab’s growing importance in the biopharma business, as it’s the only facility on campus meeting FDA “good manufacturing practices” rules for large-scale manufacturing of biological therapies.
Carl Ross has been selected to serve as managing director of Waisman Biomanufacturing. His appointment started July 1, following more than a year as its interim director. Located at the University of Wisconsin–Madison Waisman Center, the primary mission of Waisman Biomanufacturing is to help UW scientists and others efficiently translate scientific discoveries into early-stage clinical …
